Ratifi English Iniciar sesión
Ratifi

Proyectos federales de Congress.gov. Proyectos estatales de Open States.

HB 2162Sesión 2025-2026

Qué cambió entre versiones

8 párrafos cambiaron+574 palabras agregadas−546 eliminadas

El texto resaltado se agregó en la versión más reciente. El texto tachado se eliminó.

See other bills

under the

same topic

PRINTER'S NO. 2805 THE GENERAL ASSEMBLY OF PENNSYLVANIAHOUSE BILL No.2162 Session of 2026 INTRODUCED BY BOROWSKI, FRIEL, KUTZ, VENKAT, MAYES, MERSKI, PIELLI, HILL-EVANS, PROBST, GUZMAN, BURGOS, SANCHEZ, BRENNAN, MADDEN, CEPEDA-FREYTIZ, GALLAGHER, BOYD AND INGLIS, JANUARY 28, 2026 REFERRED TO COMMITTEE ON HEALTH, JANUARY 28, 2026 AN ACTAmending the act of December 14, 1992 (P.L.1116, No.145), entitled "An act providing minimum standards, terms and conditions for the licensing of persons who engage in wholesale distributions in interstate commerce of prescription drugs; and making a repeal," further providing for definitions and for license application.The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows:Section 1. The definition of "virtual manufacturer" in section 3 of the act of December 14, 1992 (P.L.1116, No.145), known as the Wholesale Prescription Drug Distributors License Act, added October 16, 2024 (P.L.988, No.101), is amended to read:Section 3. Definitions.The following words and phrases when used in this act shall have the meanings given to them in this section unless the context clearly indicates otherwise:* * *"Virtual manufacturer." A person with a place of business 12345678910111213141516171819

located in this Commonwealth in the business of manufacturing and distributing a drug or medical device that:(1) Holds the drug or device approval and label code or is otherwise identified on the product label from the United States Food and Drug Administration[.] or has submitted an application to the United States Food and Drug Administration for approval of the drug or device or intends to submit an application for approval within 12 months.(2) At no time takes physical possession of any drug or device in this Commonwealth.* * *Section 2. Section 5(a) of the act is amended by adding paragraphs to read:Section 5. License application.(a) Information on application.--An applicant for a license shall provide the following information on a license application form approved by the department:* * * (6.2) If the applicant is a manufacturer of a prescription drug that has not been approved by the United States Food and Drug Administration, a statement that the applicant has submitted an application to the United States Food and Drug Administration for approval of the prescription drug or that the applicant intends to submit an application for approval within 12 months. The department may not require approval of a prescription drug by the United States Food and Drug Administration as a condition of licensure under this act.(6.3) If the applicant is a virtual manufacturer of a drug or medical device and does not hold the drug or device 20260HB2162PN2805 - 2 - 123456789101112131415161718192021222324252627282930

approval and label code or is not otherwise identified on the product label from the United States Food and Drug Administration, a statement that the applicant has submitted an application to the United States Food and Drug Administration for approval of the drug or device or that the applicant intends to submit an application for approval within 12 months. The department may not require approval of a drug or medical device by the United States Food and Drug Administration as a condition of licensure under this act.* * *Section 3. This act shall take effect in 60 days.20260HB2162PN2805 - 3 - 1234567891011

H2162B2805A03371 LKK:EJH 06/01/26 #90 A03371AMENDMENTS TO HOUSE BILL NO. 2162Sponsor: REPRESENTATIVE BOROWSKIPrinter's No. 2805Amend Bill, page 1, lines 9 through 13, by striking out all of said lines and inserting Section 1. Section 3 of the act of December 14, 1992 (P.L.1116, No.145), known as the Wholesale Prescription Drug Distributors License Act, is amended by adding a definition to read:Amend Bill, page 1, line 19; page 2, lines 1 through 10; by striking out all of said lines on said pages and inserting "Conditional license." A temporary license issued by the department to a manufacturer or a virtual manufacturer for a drug or medical device that has not yet received final approval from the United States Food and Drug Administration.Amend Bill, page 2, lines 12 through 30; page 3, lines 1 through 10; by striking out all of said lines on said pages and inserting Section 2. Section 5 of the act is amended by adding a subsection to read:Section 5. License application.* * *(a.2) Conditional license.--(1) If the applicant is a manufacturer of a prescription drug or a virtual manufacturer of a drug or medical device that has not yet received approval from the United States Food and Drug Administration, the department may issue a conditional license if the applicant submits all of the following:(i) Documentation demonstrating that an application for approval has been submitted to the United States Food and Drug Administration, including, where applicable:(A) a new drug application number;(B) an abbreviated new drug application number;(C) a biologics license application number;(D) a unique device identification number; or2026/90LKK/HB2162A03371 - 1 -123456789101112131415161718192021222324252627282930313233

(E) other documentation acceptable to the department demonstrating active review by the United States Food and Drug Administration.(ii) Documentation identifying any contract manufacturing organization or licensed manufacturing facility involved in the manufacture, packaging, labeling or distribution of the drug or medical device.(iii) Documentation demonstrating compliance with applicable requirements of 21 U.S.C. Ch. 9 Subch. V Pt. H (relating to pharmaceutical distribution supply chain).(2) A conditional license issued under paragraph (1):(i) shall expire one year after issuance unless renewed by the department;(ii) shall automatically expire upon denial, withdrawal or refusal of the applicant's approval application by the United States Food and Drug Administration;(iii) may not authorize commercial distribution of a drug or device unless otherwise permitted under Federal law; and(iv) does not create a property interest in the conditional license and may be suspended or revoked by the department for failure to maintain compliance with this act or applicable Federal law.(3) An applicant issued a conditional license under paragraph (1) shall notify the department within five business days of:(i) approval, denial, withdrawal or refusal of an application by the United States Food and Drug Administration; or(ii) any material change to the applicant's manufacturing or distribution arrangements.(4) Issuance of a conditional license or a license under this subsection may not be construed as approval, endorsement or authorization of a drug or medical device by the Commonwealth.(5) The department may promulgate regulations and develop monitoring, reporting and enforcement procedures necessary to implement this subsection.(6) Upon satisfactory proof provided by the conditional licensee to the department that all conditions for licensure have been met, the department shall convert the conditional license into a license within 30 days.* * *2026/90LKK/HB2162A03371 - 2 -1234567891011121314151617181920212223242526272829303132333435363738394041424344

Volver al texto completo